[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614624":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":152,"collaborators":10,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":156,"sex":162,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":10,"studyType":168,"phases":10,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Secukinumab",null,"Patients with moderate-to-severe HS who are prescribed secukinumab in Canadian routine clinical practice",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":20},[23,37,42,51,60,69,78,86,94,102,110,118,126,135,143],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Novartis Investigative Site","RECRUITING","Calgary","Alberta","T2J 7E1","Canada","CA",{"type":32,"coordinates":33},"Point",[34,35],-114.08529,51.05011,{"lat":35,"lon":34},{"facility":24,"status":25,"city":26,"state":27,"zip":38,"country":29,"countryCode":30,"cosmosGeoPoint":39,"geoPoint":41,"contacts":10},"T3E 0B2",{"type":32,"coordinates":40},[34,35],{"lat":35,"lon":34},{"facility":24,"status":25,"city":43,"state":44,"zip":45,"country":29,"countryCode":30,"cosmosGeoPoint":46,"geoPoint":50,"contacts":10},"Winnipeg","Manitoba","R3M 3Z4",{"type":32,"coordinates":47},[48,49],-97.14704,49.8844,{"lat":49,"lon":48},{"facility":24,"status":25,"city":52,"state":53,"zip":54,"country":29,"countryCode":30,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Fredericton","New Brunswick","E3B 1G9",{"type":32,"coordinates":56},[57,58],-66.66558,45.94541,{"lat":58,"lon":57},{"facility":24,"status":25,"city":61,"state":62,"zip":63,"country":29,"countryCode":30,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"St. John's","Newfoundland and Labrador","A1E 1V4",{"type":32,"coordinates":65},[66,67],-52.70931,47.56494,{"lat":67,"lon":66},{"facility":24,"status":25,"city":70,"state":71,"zip":72,"country":29,"countryCode":30,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Cobourg","Ontario","K9A 4J9",{"type":32,"coordinates":74},[75,76],-78.16515,43.95977,{"lat":76,"lon":75},{"facility":24,"status":25,"city":79,"state":71,"zip":80,"country":29,"countryCode":30,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"Hamilton","L8P4B4",{"type":32,"coordinates":82},[83,84],-79.84963,43.25011,{"lat":84,"lon":83},{"facility":24,"status":25,"city":87,"state":71,"zip":88,"country":29,"countryCode":30,"cosmosGeoPoint":89,"geoPoint":93,"contacts":10},"London","N6H 5L5",{"type":32,"coordinates":90},[91,92],-81.23304,42.98339,{"lat":92,"lon":91},{"facility":24,"status":25,"city":95,"state":71,"zip":96,"country":29,"countryCode":30,"cosmosGeoPoint":97,"geoPoint":101,"contacts":10},"Markham","L3P 1X3",{"type":32,"coordinates":98},[99,100],-79.2663,43.86682,{"lat":100,"lon":99},{"facility":24,"status":25,"city":103,"state":71,"zip":104,"country":29,"countryCode":30,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"Mississauga","L4W 0C2",{"type":32,"coordinates":106},[107,108],-79.6583,43.5789,{"lat":108,"lon":107},{"facility":24,"status":25,"city":111,"state":71,"zip":112,"country":29,"countryCode":30,"cosmosGeoPoint":113,"geoPoint":117,"contacts":10},"Richmond Hill","L4C 9M7",{"type":32,"coordinates":114},[115,116],-79.43725,43.87111,{"lat":116,"lon":115},{"facility":24,"status":25,"city":119,"state":71,"zip":120,"country":29,"countryCode":30,"cosmosGeoPoint":121,"geoPoint":125,"contacts":10},"Toronto","M4E 1R7",{"type":32,"coordinates":122},[123,124],-79.39864,43.70643,{"lat":124,"lon":123},{"facility":24,"status":25,"city":127,"state":128,"zip":129,"country":29,"countryCode":30,"cosmosGeoPoint":130,"geoPoint":134,"contacts":10},"Saint-Jérôme","Quebec","J7Z 7E2",{"type":32,"coordinates":131},[132,133],-74.00365,45.78036,{"lat":133,"lon":132},{"facility":24,"status":25,"city":136,"state":128,"zip":137,"country":29,"countryCode":30,"cosmosGeoPoint":138,"geoPoint":142,"contacts":10},"Sherbrooke","J1L 0H8",{"type":32,"coordinates":139},[140,141],-71.89908,45.40008,{"lat":141,"lon":140},{"facility":24,"status":25,"city":144,"state":145,"zip":146,"country":29,"countryCode":30,"cosmosGeoPoint":147,"geoPoint":151,"contacts":10},"Saskatoon","Saskatchewan","S7N0N5",{"type":32,"coordinates":148},[149,150],-106.66892,52.13238,{"lat":150,"lon":149},{"type":153,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614624","real-world-secukinumab-outcomes-in-canadian-hs-patients-100614624",false,"NCT07282015","Real-world Secukinumab Outcomes in Canadian HS Patients","A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE)","HS-RISE","Inclusion Criteria:\n\n1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.\n2. Adult patients at the time of informed consent signature.\n3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.\n4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.\n5. Patients who can understand written and spoken Canadian English or French.\n\nExclusion Criteria:\n\n1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.\n2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.\n3. Patients who have had any prior exposure to secukinumab (i.e., \\>7 days prior to the baseline visit).","ALL","18 Years","100 Years",{"count":166,"type":167},142,"ESTIMATED","OBSERVATIONAL","The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.",[171],"Hidradenitis Suppurativa",[171,173,174,175],"NIS","secukinumab","Phase IV","2026-06-19",{"date":178,"type":179},"2026-06-23","ACTUAL",{"date":181,"type":179},"2025-12-12",{"date":183,"type":167},"2028-02-11",{"name":14,"class":6},15]